vs
CULP INC（CULP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
CULP INC的季度营收约是REGENXBIO Inc.的1.8倍（$53.2M vs $30.3M），CULP INC净利率更高（-8.1% vs -221.3%，领先213.2%），REGENXBIO Inc.同比增速更快（43.0% vs -4.4%），CULP INC自由现金流更多（$-510.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -6.2%）
Culp Inc是全球领先的纺织品制造商，主营住宅及商用家具装饰面料、床垫面料产品，为家具生产商、床上用品供应商提供配套原材料，业务覆盖北美、亚洲、欧洲等主要市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CULP vs RGNX — 直观对比
营收规模更大
CULP
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出47.4%
-4.4%
净利率更高
CULP
高出213.2%
-221.3%
自由现金流更多
CULP
多$52.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.2M | $30.3M |
| 净利润 | $-4.3M | $-67.1M |
| 毛利率 | 10.9% | — |
| 营业利润率 | -6.5% | -190.0% |
| 净利率 | -8.1% | -221.3% |
| 营收同比 | -4.4% | 43.0% |
| 净利润同比 | 23.7% | -31.2% |
| 每股收益（稀释后） | $-0.34 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CULPRGNX
| Q4 25 | $53.2M | $30.3M | ||
| Q3 25 | $50.7M | $29.7M | ||
| Q2 25 | $48.8M | $21.4M | ||
| Q1 25 | $52.3M | $89.0M | ||
| Q4 24 | $55.7M | $21.2M | ||
| Q3 24 | $56.5M | $24.2M | ||
| Q2 24 | $49.5M | $22.3M | ||
| Q1 24 | $60.4M | $15.6M |
净利润CULPRGNX
| Q4 25 | $-4.3M | $-67.1M | ||
| Q3 25 | $-231.0K | $-61.9M | ||
| Q2 25 | $-2.1M | $-70.9M | ||
| Q1 25 | $-4.1M | $6.1M | ||
| Q4 24 | $-5.6M | $-51.2M | ||
| Q3 24 | $-7.3M | $-59.6M | ||
| Q2 24 | $-4.9M | $-53.0M | ||
| Q1 24 | $-3.2M | $-63.3M |
毛利率CULPRGNX
| Q4 25 | 10.9% | — | ||
| Q3 25 | 14.3% | — | ||
| Q2 25 | 15.7% | — | ||
| Q1 25 | 12.1% | — | ||
| Q4 24 | 10.8% | 70.2% | ||
| Q3 24 | 9.0% | 48.8% | ||
| Q2 24 | 10.5% | 52.5% | ||
| Q1 24 | 12.7% | 72.6% |
营业利润率CULPRGNX
| Q4 25 | -6.5% | -190.0% | ||
| Q3 25 | 3.2% | -176.3% | ||
| Q2 25 | -4.6% | -296.3% | ||
| Q1 25 | -7.4% | 13.6% | ||
| Q4 24 | -9.7% | -242.1% | ||
| Q3 24 | -12.1% | -256.6% | ||
| Q2 24 | -8.6% | -251.3% | ||
| Q1 24 | -2.9% | -408.8% |
净利率CULPRGNX
| Q4 25 | -8.1% | -221.3% | ||
| Q3 25 | -0.5% | -208.3% | ||
| Q2 25 | -4.2% | -331.8% | ||
| Q1 25 | -7.9% | 6.8% | ||
| Q4 24 | -10.1% | -241.3% | ||
| Q3 24 | -12.8% | -246.3% | ||
| Q2 24 | -9.8% | -237.7% | ||
| Q1 24 | -5.3% | -405.4% |
每股收益（稀释后）CULPRGNX
| Q4 25 | $-0.34 | $-1.30 | ||
| Q3 25 | $-0.02 | $-1.20 | ||
| Q2 25 | $-0.17 | $-1.38 | ||
| Q1 25 | $-0.33 | $0.12 | ||
| Q4 24 | $-0.45 | $-0.99 | ||
| Q3 24 | $-0.58 | $-1.17 | ||
| Q2 24 | $-0.39 | $-1.05 | ||
| Q1 24 | $-0.26 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.6M | $102.7M |
| 总资产 | $125.2M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CULPRGNX
| Q4 25 | $10.7M | $230.1M | ||
| Q3 25 | $11.1M | $274.2M | ||
| Q2 25 | $5.6M | $323.3M | ||
| Q1 25 | $5.3M | $267.9M | ||
| Q4 24 | $10.5M | $234.7M | ||
| Q3 24 | $13.5M | $255.5M | ||
| Q2 24 | $10.0M | $290.4M | ||
| Q1 24 | $12.6M | $338.7M |
股东权益CULPRGNX
| Q4 25 | $53.6M | $102.7M | ||
| Q3 25 | $57.6M | $161.5M | ||
| Q2 25 | $57.6M | $213.7M | ||
| Q1 25 | $59.6M | $274.2M | ||
| Q4 24 | $63.6M | $259.7M | ||
| Q3 24 | $69.1M | $301.4M | ||
| Q2 24 | $76.1M | $348.3M | ||
| Q1 24 | $80.8M | $390.7M |
总资产CULPRGNX
| Q4 25 | $125.2M | $453.0M | ||
| Q3 25 | $126.4M | $525.2M | ||
| Q2 25 | $123.4M | $581.0M | ||
| Q1 25 | $127.6M | $490.9M | ||
| Q4 24 | $129.0M | $466.0M | ||
| Q3 24 | $129.1M | $519.1M | ||
| Q2 24 | $132.1M | $569.4M | ||
| Q1 24 | $142.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-471.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-510.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -1.0% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-17.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CULPRGNX
| Q4 25 | $-471.0K | $-52.3M | ||
| Q3 25 | $-695.0K | $-56.0M | ||
| Q2 25 | $-8.2M | $-49.3M | ||
| Q1 25 | $-6.8M | $33.6M | ||
| Q4 24 | $-2.4M | $-31.6M | ||
| Q3 24 | $-206.0K | $-40.5M | ||
| Q2 24 | $-2.3M | $-45.5M | ||
| Q1 24 | $-1.5M | $-55.5M |
自由现金流CULPRGNX
| Q4 25 | $-510.0K | $-52.8M | ||
| Q3 25 | $-874.0K | $-56.5M | ||
| Q2 25 | $-8.7M | $-49.7M | ||
| Q1 25 | $-7.7M | $32.6M | ||
| Q4 24 | $-3.5M | $-32.7M | ||
| Q3 24 | $-707.0K | $-40.9M | ||
| Q2 24 | $-2.7M | $-46.0M | ||
| Q1 24 | $-2.8M | $-56.0M |
自由现金流率CULPRGNX
| Q4 25 | -1.0% | -174.0% | ||
| Q3 25 | -1.7% | -189.9% | ||
| Q2 25 | -17.9% | -232.8% | ||
| Q1 25 | -14.6% | 36.6% | ||
| Q4 24 | -6.3% | -154.2% | ||
| Q3 24 | -1.3% | -168.9% | ||
| Q2 24 | -5.5% | -206.2% | ||
| Q1 24 | -4.6% | -358.5% |
资本支出强度CULPRGNX
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 1.6% | 1.2% | ||
| Q4 24 | 1.9% | 5.1% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 2.1% | 3.6% |
现金转化率CULPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CULP
| Bedding Fabrics | $30.8M | 58% |
| Upholstery | $22.4M | 42% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
